#Pharma #GLP1 #ObesityTreatment #DrugDevelopment #HealthcareInnovation #EliLilly #NovoNordisk #PharmaceuticalIndustry To view or add a comment, sign in NEW DRUG APPROVAL ALERT The FDA has approved Foundayo (orforglipron), a new once-daily oral GLP-1 for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition
As fitness and pharma converge, new models are emerging
(2003) demonstrated that Epithalon increased telomerase activity in human somatic cells by 2.4-fold A 15-year follow-up study of elderly patients showed that those receiving peptide bioregulators (including Epithalon) had a 28% reduction in mortality compared to controls Animal studies have shown increased lifespan of up to 13.3% in organisms treated with Epithalon, as reported in research published through the National Institute on Aging Studies on retinal pigment epithelium cells showed Epithalons ability to reactivate telomerase in senescent cells While more large-scale human clinical trials are needed, the existing body of research is substantial and encouraging
Form Reconstituted vial Temperature 35.6 to 46.4 F (2 to 8 C) Note Refrigerate
Probably, the best research so far is a rigorous 12 week clinical trial on 30 ASD patients aged 3 to 8 years
There is altered energy balance and reduced levels of ATP